Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2014.12.05
- VernacularTitle:ALK阳性非小细胞肺癌靶向治疗研究进展
- Author:
MA LI
1
;
ZHANG SHUCAI
Author Information
1. 101149 北京，首都医科大学附属北京胸科医院，北京市结核病胸部肿瘤研究所肿瘤内科
- Keywords:
ALK;
Lung neoplasms;
Crizotinib
- From:
Chinese Journal of Lung Cancer
2014;(12):850-854
- CountryChina
- Language:Chinese
-
Abstract:
hTe rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. hTe ifrst-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors repre-sent a signiifcant advance in the evolution of personalized medicine for NSCLC. A randomized phase III clinical trial in which superiority of crizotinib over chemotherapy was seen in previously treated ALK-positive NSCLC patients demonstrated dura-ble responses and well tolerance in the majority of ALK-positive NSCLC patients treated with crizotinib. However, despite the initial responses, most patients develop acquired resistance to crizotinib. Several novel therapeutic approaches targeting ALK-positive NSCLC are currently under evaluation in clinical trials, including second-generation ALK inhibitors, such as LDK378, CH5424802 (RO5424802), and AP26113, and new agents shock protein 90 inhibitors. hTis review aims to present the current knowledge on this fusion gene, the treatment advances, and novel drug clinical trials in ALK rearranged NSCLC.
